MicroRNA-155 Expression has Prognostic Value in Patients with Non-small Cell Lung Cancer and Digestive System Carcinomas

  • Xu, Tong-Peng (Department of Oncology, the First Affiliated Hospital of Nanjing Medical University) ;
  • Zhu, Can-Hong (Department of Gerontology, Affiliated People's Hospital of Jiangsu University) ;
  • Zhang, Jian (Department of General Surgery, Huai'an First People's Hospital, Nanjing Medical University) ;
  • Xia, Rui (Department of Biochemistry and Molecular Biology, Nanjing Medical University) ;
  • Wu, Feng-Lei (Department of Oncology, First People Hospital of Lianyungang, Lianyungang, Jiangsu Province) ;
  • Han, Liang (Department of Oncology, the First Affiliated Hospital of Nanjing Medical University) ;
  • Shen, Hua (Department of Oncology, the First Affiliated Hospital of Nanjing Medical University) ;
  • Liu, Ling-Xiang (Department of Oncology, the First Affiliated Hospital of Nanjing Medical University) ;
  • Shu, Yong-Qian (Department of Oncology, the First Affiliated Hospital of Nanjing Medical University)
  • Published : 2013.12.31


Objective: Published data have shown that microRNAs (miRNAs) could play a potential role as diagnostic and prognostic indicators in cancers. Data for the predictive value of microRNA-155 are inconclusive. The aim of the present analysis was therefore to evaluate the role of miR-155 in prognosis for patients with a variety of carcinomas. Methods: Relevant studies were identified by searching PubMed and EMBASE. Data were extracted from studies comparing overall survival (OS), recurrence-free survival (RFS) or cancer-specific survival (CSS) in patients with carcinoma with higher miR-155 expression and those with lower levels. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) of miR-155 for clinical outcome were calculated. Results: A total of 15 studies were included. The pooled hazard ratio (HR) for OS of higher miR-155 expression in cancerous tissue was 1.89 (95% CI: 1.20-2.99, P=0.006), which could markedly predict poorer survival in general cancer. For RFS/CSS, elevated miR-155 was also associated with poor prognosis of cancer (HR=1.50, 95% CI: 1.10-2.05, P=0.01). On subgroup analysis, the pooled HR for OS in non-small cell lung cancer (NSCLC) was 2.09 (95% CI: 0.68-6.41, P > 0.05), but for RFS/CSS was 1.28 (95% CI: 1.05-1.55, P=0.015), with statistical significance; the pooled HRs for OS and RFS/CSS in digestive system neoplasms were 3.04 (95% CI: 1.48-6.24, P=0.003) and 2.61 (95% CI: 1.98-3.42, P<0.05), respectively. Conclusions: The results indicated that the miR-155 expression level plays a prognostic role in patients with cancer, especially NSCLCs and digestive system carcinomas.


  1. Ambros V (2003). MicroRNAs pathways in flies and worms: growth, death, fat, stress, and timing. Cell, 113, 673-6.
  2. Calin GA, Croce CM (2006). MicroRNA-cancer connection: the beginning of a new tale. Cancer Res, 66, 7390-4.
  3. Chen CZ (2005). MicroRNAs as oncogenes and tumor suppressors. N Engl J Med, 353, 1768-71.
  4. Chen J, Wang BC, Tang JH (2012). Clinical significance of microRNA-155 expression in human breast cancer. J Surg Oncol, 106, 260-6.
  5. Donnem T, Eklo K, Berg T, et al (2011). Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization. J Transl Med, 9, 6.
  6. Du ZM, Hu LF, Wang HY, et al (2011). Upregulation of MiR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and downregulates a negative prognostic Marker JMJD1A. PLoS One, 6, e19137.
  7. Esquela-Kerscher A, Slack FJ (2006). Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer, 6, 259-69.
  8. Gironella M, Seux M, Xie MJ, et al (2007). Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155 and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA, 104, 16170-5.
  9. Greither T, Grochola LF, Udelnow A, et al (2010). Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer, 126, 73-80.
  10. Han ZB, Chen HY, Fan JW, et al (2012). Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol, 138, 153-61.
  11. Hayes DF, Isaacs C, Stearns V (2000). Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia, 6, 375-92.
  12. Huang YH, Lin KH, Chen HC, et al (2012). Identification of postoperative prognostic MicroRNA predictors in hepatocellular carcinoma. PLoS One, 7, e37188.
  13. Iorio MV, Ferracin M, Liu CG, et al (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65, 7065-70.
  14. Ishihara K, Sasaki D, Tsuruda K, et al (2012). Impact of miR- 155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemia. Cancer Epidemiol, 36, 560-5.
  15. Jiang S, Zhang HW, Lu MH, et al (2010). MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res, 70, 3119-27.
  16. Jung I, Aguiar RC (2009). MicroRNA-155 expression and outcome in diffuse large B-cell lymphoma. Br J Haematol, 144, 138-40.
  17. Kong W, Yang H, He L, et al (2008). MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol, 28, 6773-84.
  18. Lee EJ, Gusev Y, Jiang J, et al (2007). Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer, 120, 1046-54.
  19. Lee RC, Feinbaum RL, Ambros V, et al (1993). Elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75, 843-54.
  20. Monsalvez V, Montes-Moreno S, Artiga MJ, et al (2013). MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. Mod Pathol, 26, 171-81.
  21. Nana-Sinkam P, Croce CM (2010). MicroRNAs in diagnosis and prognosis in cancer: what does the future hold? Pharmacogenomics, 11, 667-9.
  22. Nikiforova MN, Tseng GC, Steward D, et al (2008). MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab, 93, 1600-8.
  23. O'Connell RM, Rao DS, Chaudhuri AA, et al (2008). Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med, 205, 585-594.
  24. Ovcharenko D, Kelnar K, Johnson C, et al (2007). Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL- induced apoptosis pathway. Cancer Res, 67, 10782-8.
  25. Papaconstantinou IG, Manta A, Gazouli M, et al (2013). Expression of MicroRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas, 42, 67-71.
  26. Raponi M, Dossey L, Jatkoe T, et al (2009). MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res, 69, 5776-83.
  27. Saito M, Schetter AJ, Mollerup S, et al (2011). The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res, 17, 1875-82.
  28. Shibuya H, Iinuma H, Shimada R, et al (2010). Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology, 79, 313-20.
  29. Shinmei S, Sakamoto N, Goto K, et al (2013). MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma. Int J Urol, 20, 468-77.
  30. Stang A (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses. Eur J Epidemiol, 25, 603-5.
  31. Stroup DF, Berlin JA, Morton SC, et al (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA, 283, 2008-12.
  32. Szafranska AE, Davison TS, John J, et al (2007). MicroRNA expression alterations are linked to tumorigenesis and nonneoplastic processes in pancreatic ductal adenocarcinoma. Oncogene, 26, 4442-52.
  33. Thompson RC, Herscovitch M, Zhao I, et al (2011). NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway. J Biol Chem, 286, 1675-82.
  34. Tierney JF, Stewart LA, Ghersi D, et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 16.
  35. Voortman J, Goto A, Mendiboure J, et al (2010). MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res, 70, 8288-98.
  36. Wang QZ, Xu W, Habib N, et al (2009). Potential uses of microRNA in lung cancer diagnosis, prognosis, and therapy. Curr Cancer Drug Targets, 9, 572-94.
  37. Wang X, Tang S, Le SY, et al (2008). Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One, 3, e2557.
  38. Yamanaka Y, Tagawa H, Takahashi N, et al (2009). Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood, 114, 3265-75.
  39. Yanaihara N, Caplen N, Bowman E, et al (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9, 189-98.

Cited by

  1. MicroRNAs as Promising Biomarkers for Tumor-staging: Evaluation of MiR21 MiR155 MiR29a and MiR92a in Predicting Tumor Stage of Rectal Cancer vol.15, pp.13, 2014,
  2. Bevacizumab Concomitant with Chemotherapy is Effective in Treating Chinese Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer vol.15, pp.14, 2014,
  3. miR-421, miR-155 and miR-650: Emerging Trends of Regulation of Cancer and Apoptosis vol.15, pp.5, 2014,
  4. How to Explain the Contradiction of microRNA 200c Expression and Survival in Solid Tumors?: a Meta-analysis vol.15, pp.8, 2014,
  5. Restoration of miR-7 expression suppresses the growth of Lewis lung cancer cells by modulating epidermal growth factor receptor signaling vol.32, pp.6, 2014,
  6. MicroRNA-2 Suppresses Lewis Lung Cancer Cells Proliferation, Invasion, and Migration in Tumor-Bearing Mice vol.70, pp.3, 2014,
  7. The Value of MicroRNA-155 as a Prognostic Factor for Survival in Non-Small Cell Lung Cancer: A Meta-Analysis vol.10, pp.8, 2015,
  8. The relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism and digestive cancer risk: Insights from a meta-analysis vol.16, pp.4, 2015,
  9. Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer vol.36, pp.3, 2015,
  10. Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12 vol.36, pp.8, 2015,
  11. Critical role of miR-155/FoxO1/ROS axis in the regulation of non-small cell lung carcinomas vol.37, pp.4, 2016,
  12. The Expression of MicroRNA-155 in Plasma and Tissue Is Matched in Human Laryngeal Squamous Cell Carcinoma vol.57, pp.2, 2016,
  13. Prognostic Role of MicroRNAs in Human Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis vol.2018, pp.1875-8630, 2018,